Axsome Therapeutics AXSM Quick ratio
Quick ratio at other companies
Other financials
Where this comes from
Calculated from Axsome Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's quick ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's quick ratio?
- Axsome Therapeutics (AXSM) reported quick ratio of 1.3× in Q1 2026.
- How has Axsome Therapeutics's quick ratio changed year-over-year?
- Axsome Therapeutics's quick ratio decreased by 32.7% year-over-year, from 2× to 1.3×.
- What is the long-term trend for Axsome Therapeutics's quick ratio?
- Over 5 years (2020 to 2025), Axsome Therapeutics's quick ratio has grown at a -28.4% compound annual growth rate (CAGR), from 7.9× to 1.5×.
- What does quick ratio mean?
- Can the company cover short-term bills without having to sell inventory first?
- How do you interpret quick ratio?
- More conservative than the current ratio. A wide gap between the two flags heavy reliance on inventory to meet near-term obligations.
- How does quick ratio compare across companies?
- Most informative for inventory-heavy businesses; converges with the current ratio for firms that carry little inventory.